Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
In this multicenter trial, we will investigate the use of fludarabine plus rituximab,
followed by Campath-1H, in previously untreated patients with CLL/SLL. Patients who are
elderly, or who are considered unlikely to tolerate this combination therapy well, will
receive single agent rituximab followed by Campath-1H.